Emerging standardization in pharmacoeconomics

Clinical Therapeutics

Volumn 20, Issue 6, 1998, Pages 1194-1202

  Mullins, C Daniel ^a   Ogilvie, Shelby ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Assessment; Economics; Guidelines; Pharmacoeconomics

Indexed keywords

CONFERENCE PAPER; COST BENEFIT ANALYSIS; DATA ANALYSIS; ECONOMIC EVALUATION; MODEL; OUTCOMES RESEARCH; PHARMACOECONOMICS; POLICY; STANDARDIZATION;

EID: 0032431094     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80115-X     Document Type: Conference Paper

References (35)

1. 1. Luce BR, Simpson K. Methods of cost-effectiveness analysis: Areas of consensus and debate. Clin Ther. 1995;17:109-125.
2. 2. ABPI-Government Strategic Working Group. Guidance on Good Practice in the Conduct of Economic Evaluations of Medicines. London: Association of the British Pharmaceutical Industry; 1994.
3. 3. Proposal for Standardisation of Some Methodological Aspects of Cost-Effectiveness Analyses (CEA), Cost-Utility Analyses (CUA), and Cost-Minimization Analyses (CMA) in the Evaluation of Health Technologies and Programmes. Madrid: General Directorate of Services and Evaluation of Health Technologies and the General Directorate of Insurance and Health Planning of the Ministry of Health and Consumption; 1994.
4. 4. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics. 1995;7:1-6.
5. 5. Commonwealth Department of Human Services and Health. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Australian Government Publishing Service; 1995.
6. 6. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. Ottawa, Ontario: Canadian Coordinating Office for Health Technology Assessment; 1994.
7. 7. Task Force on Principles for Economic Analysis of Health Care Technology. A report on principles. Ann Intern Med. 1995;123:61-70.
8. 8. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
9. 9. PhRMA Task Force on the Economic Evaluation of Pharmaceuticals. Methodological and Conduct Principles for Pharmacoeconomic Research. Washington, DC: Pharmaceutical Research and Manufacturers Association; 1995.
10. 10. Reinhardt UE. Making economic evaluations respectable. Soc Sci Med. 1997;45:555-562.
11. 11. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc Sci Med. 1997;45:563-581.
12. 12. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: Evidence from the U.K. Soc Sci Med. 1997;45:583-595.
13. 13. Koopmanschap MA, Rutten FFH. Indirect costs: The consequence of production loss or increased costs of production. Med Care. 1996;34(Suppl):DS59-DS68.
14. 14. Menon D, Schubert F, Torrance GW. Canada's new guidelines for the economic evaluation of pharmaceuticals. Med Care. 1996;34(Suppl):DS77-DS86.
15. 15. Schulman KA, Llana T, Yabroff KR. Economic assessment within the clinical development program. Med Care. 1996;34(Suppl):DS89-DS95.
16. 16. Lipscomb J. The proper role for discounting: Search in progress. Med Care. 1996;34(Suppl):DS119-DS123.
17. 17. Lovatt B. The United Kingdom guidelines for the economic evaluation of medicines. Med Care. 1996;34(Suppl):DS179-DS181.
18. 18. Freund DA. Initial development of the Australian guidelines. Med Care. 1996;34(Suppl):DS211-DS215.
19. 19. Mitchell A. Update and evaluation of Australian guidelines: Government perspective. Med Care. 1996;34(Suppl):DS216-DS225.
20. 20. Rittenhouse BE. The standards debate: What have we learned? Med Care. 1996;34(Suppl):DS5-DS10.
21. 21. Rittenhouse BE. Is there a need for standardization of methods in economic evaluations of medicines? Med Care. 1996;34(Suppl):DS13-DS22.
22. 22. Rovira J. Standardization of the economic evaluation of health technologies: European developments. Med Care. 1996;34(Suppl):DS182-DS188.
23. 23. Hillman AL. Summary of economic analysis of health care technology: A report on principles. Med Care. 1996;34(Suppl):DS193-DS196.
24. 24. Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(Suppl):DS197-DS199.
25. 25. Genduso LA, Kotsanos JG. Review of health economic guidelines in the form of regulations, principles, policies and positions. Drug Inf J. 1996;30:1003-1016.
26. 26. Drummond MF, Jefferson TO, BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
27. 27. Pauly MV. Valuing health care benefits in money terms. In: Sloan FA, ed. Valuing Health Care. New York: Cambridge University Press; 1995:99-124.
28. 28. Stergachis A. Overview of cost-consequence modeling in outcomes research. Pharmacotherapy. 1995;15(Suppl):40S-42S.
29. 29. Grabowski HG, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med. 1997;45:535-544.
30. 30. Neumann PJ, Johannesson M. From principle to policy: Using cost-effectiveness analysis. Health Aff (Millwood). 1994; 13:206-214.
31. 31. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. NEJM. 1977;296:716-721.
32. 32. Russell LB. Is Prevention Better than Cure? Washington, DC: Brookings Institution; 1986.
33. 33. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. NEJM. 1997;336:92-99.
34. 34. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA, ed. Valuing Health Care. New York: Cambridge University Press; 1995:185-205.
35. 35. Viscusi WK. Discounting health effects for medical decisions. In: Sloan FA, ed. Valuing Health Care. New York: Cambridge University Press; 1995:125-147.